Sectral and Difficulty in walking - a phase IV clinical study of FDA data

Summary:

Difficulty in walking is reported as a side effect among people who take Sectral (acebutolol hydrochloride), especially for people who are male, 60+ old, have been taking the drug for 10+ years also take Omeprazole, and have Atrial fibrillation/flutter.

The phase IV clinical study analyzes which people have Difficulty in walking when taking Sectral. It is created by eHealthMe based on reports of 3,508 people who have side effects when taking Sectral from the FDA, and is updated regularly.

What is Sectral?

Sectral has active ingredients of acebutolol hydrochloride. It is often used in high blood pressure. eHealthMe is studying from 3,548 Sectral users. Check the latest studies of Sectral.

What is Difficulty in walking?

Difficulty in walking is found to be associated with 738 drugs and 975 conditions by eHealthMe. Check the latest studies of Difficulty in walking.

On May, 02, 2026

3,508 people reported to have side effects when taking Sectral.
Among them, 17 people (0.48%) have Difficulty in walking.

Could Sectral cause Difficulty in walking?

Among these 17 people:

How long have people been on Sectral when they have Difficulty in walking? *

What is the gender of people who have Difficulty in walking when taking Sectral? *

female: 35.29 %
male: 64.71 %

What is the age of people who have Difficulty in walking when taking Sectral? *

What are other drugs people take besides Sectral? *

What are other side effects people have besides Difficulty in walking? *

Malaise (a feeling of general discomfort or uneasiness): 4 people, 23.53%
Weakness: 3 people, 17.65%
Fall: 3 people, 17.65%
Confusion: 3 people, 17.65%
Haemorrhagic Stroke (stroke caused by the rupture of a blood vessel in the brain): 2 people, 11.76%
Pain In Limb: 2 people, 11.76%
Fatigue (feeling of tiredness): 2 people, 11.76%
Motormental Retardation (a slowing-down of thought and a reduction of physical work): 2 people, 11.76%
Oedema Lower Limb (fluid collection in tissue of lower leg): 2 people, 11.76%
Inflammatory Oedema Reaction (swelling from excessive accumulation of watery fluid in cells, tissue cause reaction): 2 people, 11.76%

What are the existing conditions these people have? *

Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 3 people, 17.65%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 1 person, 5.88%
Peripheral Neuropathy (damage to nerves of the peripheral nervous system): 1 person, 5.88%
Ill-Defined Disorder: 1 person, 5.88%
Essential Hypertension (primary hypertension): 1 person, 5.88%
Colon Cancer Metastatic (cancer of colon spreads to other part of body): 1 person, 5.88%

* Approximation only. Some reports may have incomplete information.

Do you take Sectral and have Difficulty in walking?

- Check whether Difficulty in walking is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Sectral:

Sectral (3,548 reports)

Browse all side effects of Sectral:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Difficulty in walking:

Difficulty in walking (738 drugs)

Browse all the conditions that are associated with Difficulty in walking:

Difficulty in walking (975 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on acebutolol hydrochloride (the active ingredients of Sectral) and Sectral (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.